InvestSMART

BCAL Diagnostics Limited (ASX: BDX) - Announcements

- Current share price for BDX : $0.060

ASX company news and announcements for BCAL Diagnostics Limited (BDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BCAL Diagnostics Limited (BDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BCAL Diagnostics Limited (BDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BCAL Diagnostics Limited (BDX)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$22 Appendix 4G and Corporate Governance Statement 28 Aug 2026 3:46PM $0.065 $0.060 fallen by 7.69%
$22 Appendix 4E and Annual Report to shareholders 28 Aug 2026 3:44PM $0.065 $0.060 fallen by 7.69%
$22 BCAL Takes Interest in Genetic Signatures to 18.46% 26 Aug 2026 8:57AM $0.052 $0.060 risen by 15.38%
$22 Change in Substantial Shareholder Notice for GSS 26 Aug 2026 8:35AM $0.052 $0.060 risen by 15.38%
$22 Notification regarding unquoted securities - BDX 25 Aug 2026 6:53PM $0.052 $0.060 risen by 15.38%
$22 Notification regarding unquoted securities - BDX 21 Aug 2026 6:27PM $0.058 $0.060 risen by 3.45%
$22 Proposed issue of securities - BDX 21 Aug 2026 6:18PM $0.058 $0.060 risen by 3.45%
$22 BCAL Secures Funding for FY2027 Update 21 Aug 2026 6:14PM $0.058 $0.060 risen by 3.45%
$22 Bioshares Conference Investor Presentation 6 Aug 2026 9:34AM $0.065 $0.060 fallen by 7.69%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jul 2026 8:38AM $0.073 $0.060 fallen by 17.81%
$22 Notification regarding unquoted securities - BDX 14 Jul 2026 6:51PM $0.076 $0.060 fallen by 21.05%
$22 Notification regarding unquoted securities - BDX 14 Jul 2026 6:44PM $0.076 $0.060 fallen by 21.05%
$22 Notification regarding unquoted securities - BDX 14 Jul 2026 6:32PM $0.076 $0.060 fallen by 21.05%
$22 Notification regarding unquoted securities - BDX 14 Jul 2026 6:20PM $0.076 $0.060 fallen by 21.05%
$22 Becoming a substantial holder for GSS 2 Jul 2026 5:13PM $0.072 $0.060 fallen by 16.67%
$22 BCAL to Acquire Shares in Genetic Signatures 2 Jul 2026 10:04AM $0.071 $0.060 fallen by 15.49%
$22 BCAL Secures Funding for FY2027 29 Jun 2026 9:57AM $0.078 $0.060 fallen by 23.08%
$22 BCAL Develops New Blood Test for Breast Cancer Recurrence 18 Jun 2026 9:52AM $0.060 $0.060 fallen by 0%
$22 Validation Agreement Signed with Sonic USA, for Breastest V2 28 May 2026 8:25AM $0.080 $0.060 fallen by 25%
$22 BCAL Launches Early Detection Cancer Platform 19 May 2026 10:09AM $0.077 $0.060 fallen by 22.08%
$22 BCAL Appoints Anne-Louise Arnett as Chief Executive Officer 11 May 2026 8:23AM $0.074 $0.060 fallen by 18.92%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 22 Apr 2026 8:50AM $0.090 $0.060 fallen by 33.33%
$22 BCAL Submits MSAC Application for Avantect Pancreatic Test 31 Mar 2026 9:11AM $0.092 $0.060 fallen by 34.78%
$22 BCAL Accelerates Rollout of Avantect Early Detection Tests 26 Mar 2026 9:19AM $0.095 $0.060 fallen by 36.84%
$22 Change of Director's Interest Notice 20 Mar 2026 5:08PM $0.092 $0.060 fallen by 34.78%

26 - 50 of 292 results

Page 2 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.